Sharon Townson - Monte Rosa Chief Officer
| GLUE Stock | USD 8.49 0.14 1.68% |
Insider
Sharon Townson is Chief Officer of Monte Rosa Therapeutics
| Age | 49 |
| Address | 321 Harrison Avenue, Boston, MA, United States, 02118 |
| Phone | 617 949 2643 |
| Web | https://www.monterosatx.com |
Sharon Townson Latest Insider Activity
Tracking and analyzing the buying and selling activities of Sharon Townson against Monte Rosa stock is an integral part of due diligence when investing in Monte Rosa. Sharon Townson insider activity provides valuable insight into whether Monte Rosa is net buyers or sellers over its current business cycle. Note, Monte Rosa insiders must abide by specific rules, including filing SEC forms every time they buy or sell Monte Rosa'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Sharon Townson over three months ago Disposition of 79000 shares by Sharon Townson of Monte Rosa at 5.71 subject to Rule 16b-3 |
Monte Rosa Management Efficiency
The company has return on total asset (ROA) of (0.2843) % which means that it has lost $0.2843 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6123) %, meaning that it created substantial loss on money invested by shareholders. Monte Rosa's management efficiency ratios could be used to measure how well Monte Rosa manages its routine affairs as well as how well it operates its assets and liabilities. As of November 24, 2024, Return On Tangible Assets is expected to decline to -0.47. In addition to that, Return On Capital Employed is expected to decline to -0.59. At present, Monte Rosa's Other Current Assets are projected to increase significantly based on the last few years of reporting.Similar Executives
| Showing other executives | INSIDER Age | ||
| James JD | Eliem Therapeutics | 58 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| David MBA | Seres Therapeutics | 63 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| Jeff Nelson | Milestone Pharmaceuticals | 43 | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Carl Langren | Lumos Pharma | 69 | |
| MD BA | Lumos Pharma | 69 | |
| Hing Wong | HCW Biologics | 70 | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Jeff York | Seres Therapeutics | N/A | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Guy Rousseau | Milestone Pharmaceuticals | N/A | |
| Lori CPA | Lumos Pharma | 40 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
| Peter Rhode | HCW Biologics | 66 | |
| Bradley JD | Lumos Pharma | 45 | |
| Susan MS | Eliem Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.28 |
Monte Rosa Therapeutics Leadership Team
Elected by the shareholders, the Monte Rosa's board of directors comprises two types of representatives: Monte Rosa inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Monte. The board's role is to monitor Monte Rosa's management team and ensure that shareholders' interests are well served. Monte Rosa's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Monte Rosa's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Filip MD, Chief Officer | ||
| Jennifer Champoux, VP Operations | ||
| Sharon Townson, Chief Officer | ||
| Edmund Dunn, Vice Controller | ||
| Markus MD, CEO President | ||
| John Castle, Chief Scientist | ||
| Magnus DPHIL, Senior Development | ||
| Philip JD, General Counsel | ||
| Andrew Funderburk, Senior Finance | ||
| JD MBA, Chief Officer | ||
| Ajim CFA, Chief Officer | ||
| Owen Wallace, Chief Officer | ||
| Silvia Buonamici, VP Biology | ||
| Phil JD, G Counsel |
Monte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Monte Rosa a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (2.88) % | ||||
| Current Valuation | 323.11 M | ||||
| Shares Outstanding | 61.44 M | ||||
| Shares Owned By Insiders | 0.70 % | ||||
| Shares Owned By Institutions | 90.66 % | ||||
| Number Of Shares Shorted | 7.84 M | ||||
| Price To Earning | 1.91 X | ||||
| Price To Book | 2.54 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.78) | Revenue Per Share 0.221 | Return On Assets (0.28) | Return On Equity (0.61) |
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.